AKT1 and prostate cancer: The ability of fenretinide to impair migration and invasion properties in vitro was previously demonstrated for human prostate cancer cells, where 4-HPR treatment downregulated FAK and AKT and enhanced β-catenin degradation leading to the suppression of its target genes, including cyclin D1, survivin and VEGF and decreasing invasive and migratory properties [16].